SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CECONI, Claudio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.068
AS - Asia 10.419
EU - Europa 6.287
SA - Sud America 1.760
Continente sconosciuto - Info sul continente non disponibili 252
AF - Africa 215
OC - Oceania 36
Totale 42.037
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.615
SG - Singapore 3.936
CN - Cina 2.624
IT - Italia 2.147
BR - Brasile 1.374
UA - Ucraina 1.265
HK - Hong Kong 944
VN - Vietnam 874
DE - Germania 713
TR - Turchia 637
GB - Regno Unito 536
FI - Finlandia 432
BD - Bangladesh 390
FR - Francia 314
RU - Federazione Russa 300
SE - Svezia 201
JP - Giappone 198
CA - Canada 185
IN - India 178
MX - Messico 163
AR - Argentina 132
ID - Indonesia 103
IQ - Iraq 80
PL - Polonia 77
ZA - Sudafrica 76
EC - Ecuador 65
PK - Pakistan 60
CO - Colombia 57
ES - Italia 57
MY - Malesia 55
PH - Filippine 51
AT - Austria 47
NL - Olanda 46
UZ - Uzbekistan 41
VE - Venezuela 40
CL - Cile 34
MA - Marocco 33
SA - Arabia Saudita 30
AU - Australia 27
JM - Giamaica 26
KE - Kenya 24
PY - Paraguay 24
KR - Corea 23
AE - Emirati Arabi Uniti 21
TN - Tunisia 21
EG - Egitto 19
GE - Georgia 18
LT - Lituania 18
PE - Perù 18
TH - Thailandia 18
JO - Giordania 16
CR - Costa Rica 15
BE - Belgio 13
NP - Nepal 12
RO - Romania 12
CZ - Repubblica Ceca 11
IE - Irlanda 11
LB - Libano 11
GT - Guatemala 10
NI - Nicaragua 10
PT - Portogallo 10
TW - Taiwan 10
AL - Albania 9
CH - Svizzera 9
HN - Honduras 9
PS - Palestinian Territory 9
TT - Trinidad e Tobago 9
DZ - Algeria 8
IL - Israele 8
IR - Iran 8
KZ - Kazakistan 8
OM - Oman 8
BG - Bulgaria 7
BO - Bolivia 7
GR - Grecia 7
KG - Kirghizistan 7
SN - Senegal 7
UY - Uruguay 7
AM - Armenia 6
BH - Bahrain 6
MD - Moldavia 6
MN - Mongolia 6
NZ - Nuova Zelanda 6
RS - Serbia 6
BS - Bahamas 5
BY - Bielorussia 5
ET - Etiopia 5
EU - Europa 5
HR - Croazia 5
KW - Kuwait 5
MM - Myanmar 5
AO - Angola 4
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
LV - Lettonia 4
PA - Panama 4
BA - Bosnia-Erzegovina 3
HU - Ungheria 3
LY - Libia 3
NO - Norvegia 3
Totale 41.738
Salva come PNG Salva come JPEG
Città #
Singapore 2.450
Woodbridge 2.378
Fairfield 2.368
Ashburn 2.110
Houston 1.370
Jacksonville 1.352
San Jose 1.151
Seattle 994
Hong Kong 928
Chandler 887
Ann Arbor 886
Wilmington 811
Cambridge 795
Santa Clara 783
Beijing 603
Dallas 561
Council Bluffs 531
Izmir 433
Nanjing 410
Princeton 350
Ho Chi Minh City 306
New York 251
Boardman 232
San Diego 232
Los Angeles 230
Milan 224
Lauterbourg 209
Hanoi 197
Tokyo 182
Rome 152
Helsinki 149
Shenyang 135
Nanchang 119
Moscow 112
São Paulo 104
Mexico City 103
Hefei 101
Chicago 88
Hebei 81
San Mateo 77
Changsha 75
Falls Church 68
Ferrara 68
Warsaw 68
Jiaxing 67
London 67
Tianjin 67
Naples 64
Toronto 61
Jinan 58
Shanghai 58
Munich 52
Zhengzhou 48
Mountain View 47
Verona 46
Montreal 43
Phoenix 41
Jakarta 40
Ningbo 40
Rio de Janeiro 40
Brooklyn 39
Bremen 38
Da Nang 38
Tashkent 38
Atlanta 37
Redwood City 37
Taizhou 37
Frankfurt am Main 36
Buffalo 35
Philadelphia 35
Johannesburg 34
The Dalles 34
Haiphong 32
Kuala Lumpur 29
Orem 29
San Francisco 29
Columbus 28
Turin 28
Chennai 27
Guangzhou 27
Norwalk 27
Baghdad 26
Addison 25
Tappahannock 25
Washington 25
Napoli 24
Denver 23
Kunming 23
Stockholm 23
Brasília 22
Curitiba 22
Hangzhou 22
Indiana 22
Porto Alegre 22
Belo Horizonte 21
Biên Hòa 21
Bologna 21
Campinas 21
Guarulhos 21
Bari 20
Totale 27.676
Salva come PNG Salva come JPEG
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.852
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 356
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 318
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review 306
2015 ESC Guidelines for the diagnosis and management of pericardial diseases The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) 295
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 282
Uric acid and coronary artery disease: An elusive link deserving further attention 260
Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review 258
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 257
Third Universal Definition of Myocardial Infarction 249
Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain 249
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 242
A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines 242
2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica] 241
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion 238
Incremental exercise using progressive versus constant pedaling rates: A study in cardlac patients 237
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 233
Third Universal Definition of Myocardial Infarction 229
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 228
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 225
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 223
Enhanced expression and activity of xanthine oxidoreductase in the failing heart. 220
The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: Study protocol for a randomized controlled trial 219
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. 218
Advanced glycation end products and its soluble receptor (sRAGE) are increased in chronic heart failure but not in chronic obstructive pulmonary disease. 204
Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention 203
Is stunning an important component of preconditioning? 203
Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) 201
Prolonged propionyl-L-carnitine pre-treatment of rabbit: Biochemical, hemodynamic and electrophysiological effects on myocardium 201
Guidelines on myocardial revascularization 199
ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study 198
Neglected COPD and chronic comorbidities in elderly patients with chronic heart failure 195
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 195
The ACE-inhibitor Perindoprilat has high selectivity for bradykinin binding sites of human somatic ACE 194
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI] 192
Multiparametric flow cytometric characterization of circulating stem cell subsets in patients with myocardial infarction: correlation with clinical and biological data 192
Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study 190
In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart 190
Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology 188
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). 187
[Heart failure: an endothelial disorder?] 186
Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? 186
Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice 185
Neuroendocrine Control of the Cardiovascular System in Heart Failure 185
Bradykinin and coronary artery disease 185
The heart rate story 185
Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents 184
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 184
Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability 183
Occurrence of oxidative stress during reperfusion of the human heart 183
[Comparative protective effect of gallopamil in myocardial ischemia and reperfusion] 183
Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium 182
Myocardial damage during ischaemia and reperfusion 180
Heart rate reduction by pharmacological If current inhibition 180
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology 180
Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies 179
Right heart failure chronically stimulates heat shock protein 72 in heart and liver but not in other tissues. 179
Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency 179
The prospective impact of chronic obstructive pulmonary disease on short-term prognosis of patients with chronic heart failure 178
Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression 178
Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE 178
Postinfarction Left Ventricular Free Wall Rupture: Original Management and Surgical Technique 177
[The double face of oxygen. An introduction to cardiac pathology caused by oxidation injury] 177
Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration. 177
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) 176
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy 176
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 175
Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction 172
Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease 172
Studio dei progenitori emopoietici circolanti in pazienti con infarto del miocardio 172
The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria 170
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients 170
Effect of superoxide generation on rat heart mitochondrial pyruvate utilization 170
Oltre la dissincronia quali fattori determinano la risposta alla terapia di resincronizzazione cardiaca? 170
Mechanisms of remodelling - A question of life (stem cell production) and death (myocyte apoptosis) - 170
Different sites of action of diltiazem, nifedipine and verapamil on myocardial, coronary and aortic muscle 169
Oxygen Free Radicals in Shock 169
Third universal definition of myocardial infarction 169
Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? 168
Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality 168
Interleukin-6, but not pentraxin 3, predicts adverse clinical outcomes on short-term prognosis of patients with incipient heart failure 168
Selective and specific I f inhibition with ivabradine: New perspectives for the treatment of cardiovascular disease 168
Oxidative stress during myocardial ischaemia and heart failure 168
Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes 168
Different outcomes of the reperfused myocardium: insights into the comments of stunning and hibernation. 167
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) 167
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease 167
Evidence against malondialdehyde bound to cellular constituents in phospholipid peroxidation 167
Ischemic Heart Disease. 130 Questions & Answers 166
New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage 166
Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure 166
Specific properties and effect of perindopril in controlling the renin-angiotensin system 166
Angiotensin II overproduction: enemy of the vessel wall 166
Left ventricular dysfunction due to stunning and hibernation in patients 165
Mechanical vs. electrical dyssynchrony for CRTselection in patients with HF 165
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina 165
The utility of echocardiography in elderly smokers with COPD and of spirometry in elderly smokers with CHF 165
Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts 164
Cellule staminali circolanti in pazienti con infarto miocardico 164
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 164
Totale 21.220
Salva come PNG Salva come JPEG
Categoria #
all - tutte 181.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 7.572
Totale 189.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.540 0 0 306 82 107 137 167 151 100 187 262 1.041
2022/20232.315 277 29 78 259 391 382 52 243 315 24 152 113
2023/20241.176 178 166 77 50 66 130 48 31 18 64 56 292
2024/20254.108 83 106 341 104 527 279 138 304 693 545 480 508
2025/202612.764 1.001 540 1.422 1.663 1.420 839 1.212 825 1.318 1.452 661 411
2026/20271.940 628 847 465 0 0 0 0 0 0 0 0 0
Totale 42.037